Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel's adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as potential predictors of long-term remission Real-world data independently collected by the ROCCA consortium during the US commercial launch of obe-cel were presented and show a high response rate and low levels of high-grade CRS and ICANS consistent with the clinical trial experience in the FELIX study LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces presentation of preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients, as well as further insights from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology (ASH) Annual Meeting.

GlobeNewsWire • Dec 8, 2025

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.

GlobeNewsWire • Dec 8, 2025

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company's Board of Directors.

GlobeNewsWire • Dec 1, 2025

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

Benzinga • Nov 25, 2025

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance1 recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”)2 for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). AUCATZYL will be available through routine commissioning by the NHS.

GlobeNewsWire • Nov 25, 2025

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

Seeking Alpha • Nov 14, 2025

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.

GlobeNewsWire • Nov 13, 2025

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

Autolus Therapeutics plc ( AUTL ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Amanda Cray Christian Itin - CEO & Director Robert Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Goonewardene - Truist Securities, Inc., Research Division Gil Blum - Needham & Company, LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Madeleine Stone - William Blair & Company L.L.C., Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good day.

Seeking Alpha • Nov 12, 2025

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patients Leadership team bolstered to support next phase of growth and optimization of business operations Conference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 12, 2025

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Zacks Investment Research • Nov 10, 2025